Current approaches to incorporation of radium-223 in clinical practice

BACKGROUND: Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years and include cytotoxic agents (e.g., docetaxel and cabazitaxel), immunotherapy (e.g., sipuleucel-T), oral hormonal therapies targeting the androgen receptor axis (e.g., enzalutamide...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, Chris, Heidenreich, Axel, Nilsson, Sten, Shore, Neal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895600/
https://www.ncbi.nlm.nih.gov/pubmed/29298991
http://dx.doi.org/10.1038/s41391-017-0020-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895600/
https://www.ncbi.nlm.nih.gov/pubmed/29298991
http://dx.doi.org/10.1038/s41391-017-0020-y

Ejemplares similares